Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2NET 1Endocrine 1

Conditions

Carcinoma, Hepatocellular 10Esophageal Squamous Cell Carcinoma 9Stomach Neoplasms 8Esophageal Neoplasms 6Pancreatic Neoplasms 5Colorectal Neoplasms 5Cholangiocarcinoma 3Biliary Tract Neoplasms 3Liver Neoplasms 2Gallbladder Neoplasms 2Digestive System Neoplasms 2Colonic Neoplasms 2SHR-1210 1Pancreatic Adenocarcinoma Metastatic 1Neuroendocrine Tumors 1Gastrointestinal Stromal Tumors 1Gastroenteropancreatic Neuroendocrine Tumor G3 1Breast Neoplasms 1Bile Duct Neoplasms 1Anlotinib 1

Interventions

Irinotecan 10Fluorouracil 10Leucovorin 9Bevacizumab 9Gemcitabine 8Paclitaxel 7Cisplatin 7Capecitabine 7Oxaliplatin 6130-nm albumin-bound paclitaxel 6Albumin-Bound Paclitaxel 5napabucasin 4Sorafenib 4Drug Therapy 4Cetuximab 4pembrolizumab 3apatinib 3Radiotherapy 3Ocoxin 3Imatinib Mesylate 3Folfox protocol 3Everolimus 3tislelizumab 2spartalizumab 2palbociclib 2entinostat 2encorafenib 2camrelizumab 2anlotinib 2Sunitinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Digestive System Neoplasms × anlotinib × Gastrointestinal × Clear all
NCT05262335 2023-11-28

ALTER-G-001

Ruijin Hospital

Phase 2 Unknown
116 enrolled
Gastrointestinal

Digestive System Neoplasms

NCT04207463 2020-06-17

A Study of Anlotinib and AK105 Injection in Subjects With Gastrointestinal Tumors, Urinary System Tumors, Neuroendocrine Tumors

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2 Unknown
150 enrolled
EndocrineGastrointestinalNET

Digestive System Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡